Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2025
Updated information about Pharmac’s priority lists (September 2025)
21 October 2025 - Pharmac’s Pūahoaho Report provides the latest information about applications for medicines, vaccines, and related products that we’ve ...
Posted by Michael Wonder on 20 Oct 2025
PHARMAC proposes greater transparency for medicine funding decisions
20 October 2025 - PHARMAC is proposing changes to bring greater transparency and clarity to how medicine funding applications are ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 09 Oct 2025
Why the Government must urgently raise the NICE cost effectiveness threshold
7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...
Posted by Michael Wonder on 08 Oct 2025
Britain prepares NHS drug spending hike to stave off Trump tariffs
8 October 2025 - The UK Government has drawn up proposals to increase the amount the National Health Service pays ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC declines inactive medicine applications
18 June 2025 - PHARMAC has declined 48 inactive funding applications so that it is clearer what medicines are currently ...
Posted by Michael Wonder on 20 May 2025
Redefining value assessment and healthcare funding priorities for medicines: the journey to patient-centric decision making in APAC – a systematic literature review
14 May 2025 - This study explored patient involvement in health care decision-making in the Asia-Pacific region by identifying roles and ...
Posted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...
Posted by Michael Wonder on 03 Apr 2025
Real-world evidence to support health technology assessment and payer decision making: is it now or never?
31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...
Posted by Michael Wonder on 17 Feb 2025
Unravelling the association between uncertainties in model-based economic analysis and funding recommendations of medicines in Australia
14 February 2025 - Health technology assessment is used extensively by the PBAC to inform medicine funding recommendations in Australia. ...
Posted by Michael Wonder on 28 Dec 2024
What price is society willing to pay for new drugs?
12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...
Posted by Michael Wonder on 18 Dec 2024
What is NICE’s severity modifier?
15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...
Posted by Michael Wonder on 16 Dec 2024
Should NICE’s cost effectiveness thresholds change?
13 December 2024 - We explore the on-going debate around NICE’s cost effectiveness thresholds and what the future holds. ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...